Examination of the mizoribine and azathioprine combination immunosuppressive therapy in primary sclerosing cholangitis

Phase 2

• Conditions: Primary sclerosing cholangitis; PSC; K830

• Registration Number: JPRN-jRCTs051180120
• Lead Sponsor: Tajiri Hitoshi

Brief Summary

In this case, the combination therapy with mizoribine and azathioprine was effective, and there were no apparent side effects in this case.

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-03-13
• Study Completion: 2020-03-31
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 1

Inclusion Criteria

1.Primary sclerosing cholangitis
2. No condition on primary disease.
3.Patients age is 18 years old from 3 years old at the agreement acquisition.
3.No condition on primary disease.
4.When there are complications such as an esophagus varix, the cirrhosis, it depends on a chief physician judgment
5.Written informed consent after adequate explanation and acceptance.

Exclusion Criteria

1.History of hypersensitivity to any ingredients of Bredinin, Imuran, or Azanin.
2.Patients with WBC less than 3000/m3.
3.Patients with severe degree of allergic diseases.
4.Patients who are assessed to be ineligible for this study by the principle investigator.

Study & Design

• Study Type: Interventional
• Study Design: Not specified